Shuttle Pharmaceuticals Holdings (SHPH) Amortizatization of Intangibles (2022 - 2026)
Shuttle Pharmaceuticals Holdings' (SHPH) quarterly Amortizatization of Intangibles came in at $12122.0 in Q1 2026, up 85.49% year-on-year from $6535.0 in Q1 2025, and down 12.92% quarter-over-quarter from $13921.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $12122.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles rose 85.49% year-over-year to $12122.0 in Q1 2026; TTM through Mar 2026 was $659978.0, a 3.05% increase from a year earlier, with the FY2025 full-year figure at $62030.0, down 94.25% from the prior year.
- Amortizatization of Intangibles eased to $12122.0 in Q1 2026 per SHPH's latest filing, from $13921.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $606974.0 in Q3 2022 and bottomed at -$508121.0 in Q4 2022.
- The 5-year median for Amortizatization of Intangibles is $316967.5 (2024), against an average of $265399.4.
- Across the five-year window, Amortizatization of Intangibles surged 337.84% in 2023 and plunged 98.53% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at -$508121.0 in 2022, then jumped by 192.17% to $468325.0 in 2023, then slumped by 47.17% to $247430.0 in 2024, then sank by 94.37% to $13921.0 in 2025, then declined by 12.92% to $12122.0 in 2026.
- Per Business Quant, the three latest SHPH Amortizatization of Intangibles figures stand at $12122.0 (Q1 2026), $13921.0 (Q4 2025), and $247430.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.45 Mn | 1.45 Mn | - | 12,122.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,122.00 |
| Mar 31, 2026 | 12,122.00 |
| Dec 31, 2025 | 13,921.00 |
| Dec 31, 2025 | 13,921.00 |
| Sep 30, 2025 | 247,430.00 |
| Sep 30, 2025 | 247,430.00 |
| Jun 30, 2025 | 386,505.00 |
| Jun 30, 2025 | 386,505.00 |
| Mar 31, 2025 | 6,535.00 |
| Mar 31, 2025 | 6,535.00 |
| Sep 30, 2024 | 247,430.00 |
| Sep 30, 2024 | 247,430.00 |
| Jun 30, 2024 | 386,505.00 |
| Jun 30, 2024 | 386,505.00 |
| Mar 31, 2024 | 445,509.00 |
| Mar 31, 2024 | 445,509.00 |
| Dec 31, 2023 | 468,325.00 |
| Dec 31, 2023 | 468,325.00 |
| Sep 30, 2023 | 538,302.00 |
| Sep 30, 2023 | 538,302.00 |